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Abstract
Occurrence of bioprosthetic valve thrombosis less than a year after replacement is very uncommon. Here, we
describe a case of a 57 year old male, who presented 10 months after receiving a bioprosthetic mitral valve repla-
cement with a two week history of dyspnea on exertion, worsening orthopnea and decreased exercise tolerance.
Echocardiography revealed severe mitral regurgitation (MR), thrombosis of the posterior mitral leaflet, left atrial (LA)
mural thrombus and a depressed left ventricular ejection fraction of twenty-five percent. Given severe clot burden
and decompensated heart failure (New York Heart Association - NYHA class III) repeat sternotomy was done to
replace the bioprosthetic mitral valve and remove LA mural thrombus. MR was resolved postoperatively. This brief
report further reviews promoting factors, established guidelines and management strategies of bioprosthetic valve
thrombosis.
Background
Bioprosthetic mitral valves are advantageous over
mechanical valves as their incidence of thrombosis, pan-
nus formation and embolic events are significantly
lower. This disparity in thromboembolic events as com-
pared to mechanical valves avoids a need for chronic
anticoagulation in many patients receiving bioprosthetic
valve replacement [1]. However, bioprosthetic mitral
valves can present with thrombosis shortly after replace-
ment in high risk patients not maintained on anticoagu-
lation, leading to severe valve incompetence and cardiac
decompensation, as noted in the following case.
Case Presentation
A 57 year old male with a past medical history of
chronic atrial fibrillation, a depressed ejection fraction
of 25%, and severe MR underwent mitral valve replace-
ment with a bioprosthetic Mosaic valve (Medtronic Inc.,
M i n n e a p o l i sM N )a n dac o m p l e t el e f ta n dr i g h ts i d e d
MAZE procedure. Post operative transthoracic echocar-
diogram (TTE) showed a competent mitral valve tissue
prosthesis and the patient was discharged on warfarin.
Anticoagulation was discontinued three months after
valve replacement and the patient remained in sinus
rhythm on electrocardiography.
Ten months following mitral valve replacement, the
patient presented with a two week history of progressive
dyspnea on exertion, orthopnea and weight gain. TTE
revealed severe mitral valve stenosis and mitral regurgi-
tation, with a mean gradient of 8.5 mmhg (max. gradi-
ent – 25.5 mmhg) across the mitral valve, and restricted
motion of mitral leaflets. On transesophageal echocar-
diogram (TEE), a mitral mass was observed on the pos-
terior leaflet along with mural thrombus in a dilated left
atrium measuring 4.90 cm in diameter (figure 1). Ejec-
tion fraction was 25%. The patient was started on inter-
venous diuretics and anticoagulation with Heparin,
however due to severity of clot burden and progressive
decompensated heart failure (NYHA class III) repeat
sternotomy was performed.
Intraoperatively, mural clot was debrided from the free
and posterior left atrial walls. The mitral bioprosthesis
was incompetent with pannus growing on the posterior
leaflet. This valve was excised and replaced with a 25
mm On-X mechanical valve (On-X Life Technologies,
Inc., Austin TX.) that functioned without leakage after
placement. Postoperatively, the patient had improved
exercise tolerance and was discharged on indefinite war-
farin therapy.
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Clinically significant bioprosthetic valve thrombosis is
considered uncommon, however, its incidence on routine
echocardiographic surveillance is reported as high as six
percent [2]. Specific risk factors that promote formation
of bioprosthetic valve thrombosis include large LA size,
atrial fibrillation leading to decreased transvalvular flow,
decreased LVEF, prior history of thromboembolic events
and a hypercoagulable diathesis [3-5]. In the present
case, two risk factors were present including an enlarged
LA measuring 4.90 cm in diameter and a decreased EF of
25%. Moreover, radioablative MAZE lines are areas of
damaged LA endothelium which can serve as a nidus for
thrombus formation. Due to the presence of several pro-
thrombotic risk factors prolonged anticoagulation with
warfarin could have assisted in prevention of thrombus
formation and valve dysfunction.
Although freedom from long term anticoagulation is a
feature of bioprosthetic valve replacement, this case calls
for a brief review of current anticoagulation guidelines
following bioprosthetic valve replacement and a radioa-
blative MAZE procedure. The 2008 American Heart
Association (AHA) and American College of Cardiology
(ACC) guidelines state that high risk patients with any
of the following risk factors including atrial fibrillation,
LV dysfunction with EF < 30%, recurrent thromboem-
bolic events or a hypercoagulable condition meet a class
I indication for indefinite anticoagulation [6]. To reduce
the risk of thrombus formation after a radio ablative
procedure for atrial fibrillation the 2007 Heart Rhythm
Society (HRS) expert consensus statement recommends
a minimum two month period of warfarin anticoagula-
tion that should be continued indefinitely if the patient’s
CHADS2 score is greater or equal to 2 [7]. These guide-
lines further emphasize a beneficial role of prolonged
anticoagulation in high risk patients.
This case also calls for frequent post operative echo-
cardiographic monitoring in non- anticoagulated
Figure 1 TEE showing mural thrombus in the left atrium and a thrombosed bioprosthetic mitral valve.
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The 2007 European Society of Cardiology (ESC) guide-
lines [8] recommend initial follow up 6-12 weeks post
operatively with TTE imaging. Thereafter, yearly clinical
assessment is prudent and repeat TTE imaging is
dependent on development of new cardiac symptoms.
TEE can be considered if TTE is of poor quality, in
cases of suspected prosthetic valve dysfunction or endo-
carditis. However, this case illustrates that high risk
patients not on prolonged anticoagulation can develop
significant thrombus and valve dysfunction prior to
becoming symptomatic. More frequent clinical cardiac
assessment and/or TTE imaging in high risk asympto-
matic patients might allow earlier detection of biopros-
thetic valve dysfunction by clot formation.
According to the 2007 ESC guidelines [8], once valve
thrombosis reaches clinically significant obstruction,
management between anticoagulation and surgery rests
on the level of critical illness. Surgery is performed in
critically ill patients unless it is not immediately avail-
able or in patients unlikely to survive surgery due to sig-
nificant co-morbidities, where fibrinolysis is considered
as an alternative. In non-critically ill patients, if their
baseline degree of anticoagulation was inadequate then
heparin and aspirin are initiated and thrombus is reas-
sessed by echocardiography. If there is no resolution of
valve thrombosis then surgery versus fibrinolysis is con-
sidered. In cases of persistent or recurrent valve throm-
bosis despite adequate anticoagulation surgical
replacement is performed.
Management of non-obstructive prosthetic valve
thrombosis depends on the occurrence of thromboem-
bolism (TE) and thrombus size [8]. Initially, anticoagula-
tion is optimized. In patients with evidence of TE,
surgery is performed immediately if thrombus size is
>10 mm, otherwise it is delayed. In patients without TE,
surgery is performed for persistent thrombus of >10
mm on adequate anticoagulation and fibrinolysis is con-
sidered in high risk patients with multiple co
morbidities.
In the present case, obstructive valve thrombosis, large
clot burden and critical illness made surgical replace-
ment a reasonable and successful treatment option.
Conclusion
Bioprosthetic mitral valve thrombosis is an under recog-
nized complication in high risk patients that leads to
rapid valve incompetence. Post-operatively, patients
must be stratified in high or low risk categories, and
anticoagulation should be maintained indefinitely for
high risk patients. If anticoagulation is not maintained
for individualized reasons then a semi-annual TTE
within the first year and annually thereafter may detect
subclinical bioprosthetic valve thrombosis in asympto-
matic patients.
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